A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

Overview

cited authors

Rodon, J.; Rodriguez, E.; Maitland, M. L.; Tsai, F. y. -c.; Socinski, M. A.; Berlin, J. D.; Thomas, J. S.; Al Baghdadi, T.; Wang, I. -m.; Guo, C.; Golmakani, M.; Clark, L. N.; Gazdoiu, M.; Li, M.; Tolcher, A. W.

authors

Socinski, Mark A., MD

Publication Date

April 1, 2024

webpage

Web of Science

published in

ESMO OPEN Journal

Research

keywords

PF-06939999
PRMT5 inhibitor
dose escalation
dose expansion
phase I
solid tumors

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.